Enlivex
Manufacturing · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Weizmann Science Park 14, Ness Ziona, Ce...Phone Number
+972 86328500Website
www.enlivex.comRevenue
$7.6 MillionStock Symbol
ENLVIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Enlivex
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments (unmet medical needs) such as sepsis and COVID-19, as well as solid tumors' immune-checkpoint rebalancing.Explore more
Enlivex Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Enlivex your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Enlivex has recently received funding, and reach out quickly before it becomes old news!
Click to see if Enlivex had a recent Job posting/layoffs
Enlivex, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Enlivex launches new products
Website visits: Recent activity has been detected on your website
Check out if Enlivex is spiking on competitors!
Funding: Get notified immidiatlly once Enlivex has new funding data
Congratulate Masked Content for being promoted to Masked Content at Enlivex
Earning: See what the market has to say on Enlivex recently announced quarterly report
Recommended Actions
Find VP level buyers at Enlivex
Find 2 more new buyers
Company Profile Activity
Activity Insights
Enlivex is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Enlivex is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Enlivex.
Enlivex financials insights
Gather financial insights about Enlivex, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Debt
$7M
2025
Stock/Share Issuance
$212M
2026
Debt
$21M
Enlivex Tech Stack
A closer look at the technologies used by Enlivex
See more technologies
Most Recent Scoops
Project
Product Development, Product Management, Intellectual Property, Legal Affairs, Pharmaceuticals
Project
Laboratory Operations, Medical Research, Clinical Operations
Partnership
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Enlivex News & Media
Enlivex Treasury Portfolio Update: RAIN Trading Volume Reaches $860MM, 622% Month-Over-Month Growth in July vs June
Nes-Ziona, Israel, July 30, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an update on the Rain protocol trading metrics. Trading volume on the Rain protocol reached $860 million, and experienced a substantial increase of 622% between the trading volume of June 2026 vs July 2026.Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones
Webinar to cover the rationale and value creation potential of the recently announced private placement, an update on Rain protocol milestones, and recent clinical progress for Allocetra™, including its new RMAT designation from the FDAEnlivex Announces $400,000,000 Private Placement
Nes-Ziona, Israel, July 28, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, “Enlivex” or “the Company”), a quality longevity company powered by a prediction markets treasury, today announced that it has entered into a securities purchase agreement with a single institutional investor with respect to the private placement of $400,000,000 of ordinary shares (or ordinary share equivalents in lieu thereof) at a price of $5.00 per share for subscription amounts funded in U.S. dollars, USDTEnlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion
Nes-Ziona, Israel, July 20, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV, "Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of July 18, 2026, the net asset value (NAV1) per ordinary share was $66.16, and the Company held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion2.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Enlivex
Sign Up For FreeTo access detailed company insights
Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome) and for which there are no approved treatments... Read More
